Recce Pharmaceuticals Limited (ASX: $RCE) has successfully dosed the first male and female participants in the next cohort with RECCE® 327 (R327) at 4,000mg intravenously (I.V.) at a fast infusion rate of 20-minutes in its Phase I/II UTI/Urosepsis clinical trial. The company has explored multiple infusion times of R327 within this clinical trial, including 15-mins, 20-mins, 30-mins, and 45-mins. This marks the highest dose (4,000mg) tested in participants in this trial with Minimum Inhibitory Concentration (MIC) activity against bacteria already identified among existing clinical samples.
The full efficacious potential of R327 via I.V. administration will be made available at the completion of this clinical trial in line with study protocol.
Recce Pharmaceuticals Limited (ASX: $RCE) has successfully dosed the first male and female participants in the next cohort with RECCE® 327 (R327) at 4,000mg intravenously (I.V.) at a fast infusion rate of 20-minutes in its Phase I/II UTI/Urosepsis clinical trial. The company has explored multiple infusion times of R327 within this clinical trial, including 15-mins, 20-mins, 30-mins, and 45-mins. This marks the highest dose (4,000mg) tested in participants in this trial with Minimum Inhibitory Concentration (MIC) activity against bacteria already identified among existing clinical samples. The full efficacious potential of R327 via I.V. administration will be made available at the completion of this clinical trial in line with study protocol.